ERBB2 and breast cancer: The low-risk OncotypeDX group had a higher HER2 IHC score than the medium-risk group, as shown in an unpaired comparison between primary and metastatic BC samples comprising all the available biopsies, based upon the OncotypeDX score category (duns p = 0.0067; Fig. 2b).